^
    Back
    Association details:
    Biomarker:KRAS G12V
    Cancer:Colon Cancer
    Drug Class:CDK9 inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    AACR-II 2020
    Title:

    6425 / 19 - Sensitivity of oncogenic KRAS-expressing cells to CDK9 inhibition identified by a phenotypic compound screen

    Published date:
    05/15/2020
    Excerpt:
    ....have specific activity against SW620 (KRASG12V) and LS513 (KRASG12D) over Colo320 (RASWT) colon cancer cell lines….we identified sensitivity of oncogenic KRAS-expressing cell to CDK9 inhibitors…